Similarly, recent studies undertaken in people with T2D and heart failure (HF) have also observed a slower decline in kidney function in participants receiving SGLT2 inhibitors as well as a lower incidence of CKD and kidney failure (9, 10). This evidence concerns the gene SLC5A2 and hydrops fetalis.